BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37394919)

  • 1. Chromatin Organization and Transcriptional Programming of Breast Cancer Cell Identity.
    Bobbitt JR; Seachrist DD; Keri RA
    Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37394919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes.
    Xi Y; Shi J; Li W; Tanaka K; Allton KL; Richardson D; Li J; Franco HL; Nagari A; Malladi VS; Coletta LD; Simper MS; Keyomarsi K; Shen J; Bedford MT; Shi X; Barton MC; Kraus WL; Li W; Dent SYR
    BMC Genomics; 2018 Feb; 19(1):150. PubMed ID: 29458327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
    Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.
    Kalyuga M; Gallego-Ortega D; Lee HJ; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Launchbury R; Statham AL; Armstrong N; Alles MC; Young A; Egger A; Au W; Piggin CL; Evans CJ; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JM; Nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ
    PLoS Biol; 2012; 10(12):e1001461. PubMed ID: 23300383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel subtype classification and risk of breast cancer by histone modification profiling.
    Chen X; Hu H; He L; Yu X; Liu X; Zhong R; Shu M
    Breast Cancer Res Treat; 2016 Jun; 157(2):267-279. PubMed ID: 27178334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain.
    Cai WL; Greer CB; Chen JF; Arnal-Estapé A; Cao J; Yan Q; Nguyen DX
    BMC Med Genomics; 2020 Mar; 13(1):33. PubMed ID: 32143622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
    Pal B; Chen Y; Bert A; Hu Y; Sheridan JM; Beck T; Shi W; Satterley K; Jamieson P; Goodall GJ; Lindeman GJ; Smyth GK; Visvader JE
    Breast Cancer Res; 2015 Jun; 17(1):85. PubMed ID: 26080807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
    Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
    Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative characterization of 3D chromatin organization in triple-negative breast cancers.
    Kim T; Han S; Chun Y; Yang H; Min H; Jeon SY; Kim JI; Moon HG; Lee D
    Exp Mol Med; 2022 May; 54(5):585-600. PubMed ID: 35513575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
    Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
    Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation.
    Ruff GL; Murphy KE; Smith ZR; Vertino PM; Murphy PJ
    BMC Cancer; 2021 Dec; 21(1):1342. PubMed ID: 34922480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
    Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
    Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.
    Montes de Oca R; Gurard-Levin ZA; Berger F; Rehman H; Martel E; Corpet A; de Koning L; Vassias I; Wilson LO; Meseure D; Reyal F; Savignoni A; Asselain B; Sastre-Garau X; Almouzni G
    Mol Oncol; 2015 Mar; 9(3):657-74. PubMed ID: 25497280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of histopathological images and chromatin accessibility data for estrogen receptor-positive breast cancer.
    Xu S; Lu Z; Shao W; Yu CY; Reiter JL; Feng Q; Feng W; Huang K; Liu Y
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):195. PubMed ID: 33371906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
    Erdős E; Bálint BL
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis.
    Aylon Y; Furth N; Mallel G; Friedlander G; Nataraj NB; Dong M; Hassin O; Zoabi R; Cohen B; Drendel V; Salame TM; Mukherjee S; Harpaz N; Johnson R; Aulitzky WE; Yarden Y; Shema E; Oren M
    Nat Commun; 2022 Nov; 13(1):7199. PubMed ID: 36443319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranuclear and higher-order chromatin organization of the major histone gene cluster in breast cancer.
    Fritz AJ; Ghule PN; Boyd JR; Tye CE; Page NA; Hong D; Shirley DJ; Weinheimer AS; Barutcu AR; Gerrard DL; Frietze S; van Wijnen AJ; Zaidi SK; Imbalzano AN; Lian JB; Stein JL; Stein GS
    J Cell Physiol; 2018 Feb; 233(2):1278-1290. PubMed ID: 28504305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
    Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
    Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
    PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.
    Osmanbeyoglu HU; Shimizu F; Rynne-Vidal A; Alonso-Curbelo D; Chen HA; Wen HY; Yeung TL; Jelinic P; Razavi P; Lowe SW; Mok SC; Chiosis G; Levine DA; Leslie CS
    Nat Commun; 2019 Sep; 10(1):4369. PubMed ID: 31554806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.